Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels

被引:12
|
作者
Kuriyama, M [1 ]
Uno, H [1 ]
Watanabe, H [1 ]
Yamanaka, H [1 ]
Saito, Y [1 ]
Shida, K [1 ]
机构
[1] Gifu Univ, Sch Med, Dept Urol, Gifu 5008750, Japan
关键词
prostate cancer; PSA gray zone; F/T; PSAD; prostatic volume;
D O I
10.1093/jjco/29.12.617
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: For screening prostate cancer (CAP) using prostate-specific antigen (PSA), the indications of biopsies for patients showing slightly elevated PSA values are still controversial. Furthermore, the dependence of total PSA, free-to-total PSA ratio (F/T) and PSA density (PSAD) on prostatic volume in gray zone cases is unclear. Methods: By analyzing 1913 patients with a serum total PSA ranging from 2.0 to 20 ng/ml, we evaluated the correlation between total PSA and age or prostatic volume and positive predictive value (PPV) in each range for total PSA, age and prostatic volume. Then suitable reference values for total PSA, F/T and PSAD were decided according to prostatic volume. Results: There was no close correlation between PSA and age or volume. The PPV was high in the group with a prostatic volume of 10-30 mi. Prostatic volume was categorized into three groups, <20, 20-40 and greater than or equal to 40 ml, and reference values for obtaining a sensitivity of 90% were proposed. The reference values of total PSA and PSAD were lowered and that of F/T was raised with increase in prostatic volume. The specificity was very low for the greater than or equal to 40 mi group. The highest specificity of 36% in PSAD was obtained for the <20 ml group. Conclusion: The reference values for total PSA, F/T and PSAD must be changed according to prostatic volume in order to maintain a sufficient diagnostic sensitivity of CAP. Of these parameters, PSAD showed a high specificity in the group with a prostatic volume of <40 ml.
引用
收藏
页码:617 / 622
页数:6
相关论文
共 27 条
  • [21] Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy
    Gregorakis, AK
    Malovrouvas, D
    Stefanakis, S
    Petraki, K
    Scorilas, A
    CLINICA CHIMICA ACTA, 2005, 357 (02) : 196 - 201
  • [22] Nonpalpable (stage T1c) prostate cancer: Prediction of "insignificant" disease using free/total (F/T) serum PSA levels and biopsy findings.
    Epstein, JI
    Chan, DW
    Sokoll, LJ
    Walsh, PC
    Cox, JL
    Carter, HB
    JOURNAL OF UROLOGY, 1998, 159 (05): : 293 - 293
  • [23] Low Percentage of Free Prostate-specific Antigen (PSA) Is a Strong Predictor of Later Detection of Prostate Cancer Among Japanese Men With Serum Levels of Total PSA of 4.0 ng/mL or Less EDITORIAL COMMENT
    Loeb, Stacy
    UROLOGY, 2014, 84 (05) : 1167 - 1167
  • [24] Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10ng/mL: A meta-analysis
    Huang, Yan
    Li, Zhen-Zhen
    Huang, Ya-Liang
    Song, Hong-Jun
    Wang, You-Juan
    MEDICINE, 2018, 97 (13)
  • [25] THE PREDICTIVE VALUE OF PREOPERATIVE SERUM PSA LEVELS FOR TUMOR VOLUME AND PATHOLOGICAL STAGE IN AFRO-AMERICAN (AA) AND WHITE (W) PATIENTS WITH CLINICALLY LOCALIZED PROSTATE-CANCER
    SAKR, WA
    GRIGNON, DJ
    POWELL, IJ
    SCHOMER, KL
    PONTES, JE
    MONTIE, JE
    CRISSMAN, JD
    LABORATORY INVESTIGATION, 1995, 72 (01) : A83 - A83
  • [26] Correlation of PSA blood levels with standard uptake value maximum (SUVmax) and total metabolic tumor volume (TMTV) in 18F-PSMA-1007 and 18F-choline PET/CT in patients with biochemically recurrent prostate cancer
    Fragkiadaki, Vasiliki
    Panagiotidis, Emmanouil
    Vlontzou, Evaggelia
    Kalathas, Theodoros
    Paschali, Anna
    Kypraios, Charalampos
    Chatzipavlidou, Vasiliki
    Datseris, Ioannis
    NUCLEAR MEDICINE COMMUNICATIONS, 2024, 45 (11) : 924 - 930
  • [27] Serum values of prostate-specific antigen (PSA) and grade groups according to the International Society of Urological Pathology (ISUP grading), as determinants of [18F]DCFPyL PET/CT positivity in patients with biochemical recurrence of prostate cancer treated with radical prostatectomy.
    Penaherrera Cepeda, A.
    Diaz Gonzaga, L.
    Villanueva Curto, J.
    Badell Martinez, J.
    Garcia-Talavera San Miguel, P.
    Gomez-Caminero Lopez, F.
    Campana Diaz, E.
    Rama Alonso, S.
    Tamayo Alonso, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S532 - S532